Evolution Optiks has launched a prospective, single-site, randomised, controlled trial of its DeCon device to assess human vestibular disorders.

It will compare the performance of the neuro-optical testing device with the videonystagmography technology.

This technology is utilised to test inner ear and central motor functions by tracking movements of the eye in response to visual stimulation and changes in position.

The study will enrol up to 25 participants, who will undergo nine different tests using both devices at a clinical centre in New York.

The vestibular system consists of the inner ear and brain parts responsible for processing the sensory information involved with balance control and eye movements.

Damage or illness to these processing areas can lead to vestibular dysfunction.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Vestibular disorders often result from external brain trauma, commonly caused by events such as falls and head impacts, particularly in motor vehicle accidents or sports-related injuries.

Leveraging advanced hardware and software, the DeCon device enables the diagnosis of vestibular dysfunction by offering access to multiple neurological tests.

Evolution Optiks president and CEO Raul Mihali said: “Our DeCon unit, which is intended to be marketed under our brand name NeuroDynamiks, relies on proprietary technology that allows for tracking and analysis of involuntary movements of the eyeball in response to stimuli within the head-mounted device.

“These data are simultaneously recorded on the device and, if required, can be made available remotely for interpretation by a qualified medical practitioner.”